Login to Your Account

Evotec Finds New Partner for NMDA Drugs in Janssen Deal

By Nuala Moran
Staff Writer

Monday, December 17, 2012
A year and a half after Roche AG handed back rights, Evotec AG has found a new home for its NMDA antagonist portfolio, in a licensing deal with Janssen Pharmaceuticals Inc. worth a potential $75 million up to launch.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription